Drugs /

napabucasin

Back to Drugs List

Overview

NCI Definition [1]:
An orally available cancer cell stemness inhibitor with potential antineoplastic activity. Even though the exact target has yet to be fully elucidated, napabucasin appears to target and inhibit multiple pathways involved in cancer cell stemness. This may ultimately inhibit cancer stemness cell (CSC) growth as well as heterogeneous cancer cell growth. CSCs, self-replicating cells that are able to differentiate into heterogeneous cancer cells, appear to be responsible for the malignant growth, recurrence and resistance to conventional chemotherapies.

Clinical Trials

View Clinical Trials for napabucasin

Napabucasin has been investigated in 3 clinical trials, of which 0 are open and 3 are closed. Of the trials investigating napabucasin, 2 are phase 1/phase 2 (0 open) and 1 is phase 2 (0 open).

Microsatellite Stable (MSS) is the most frequent biomarker inclusion criterion for napabucasin clinical trials.

Colorectal adenocarcinoma, hematopoietic and lymphoid malignancy, and malignant solid tumor are the most common diseases being investigated in napabucasin clinical trials [2].

Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Napabucasin
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating napabucasin and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
bbi608, bbi-608, bb608, 2-acetylnaphtho(2,3-b)furan-4,9-dione
NCIT ID [1]:
C96429

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.